Arterra Bioscience Lifts 2025 Profit by 50% and Proposes Higher Dividend

Arterra Bioscience SpA ( (IT:ARBS) ) just unveiled an announcement.

Arterra Bioscience reported strong 2025 results, with value of production rising 16.12% to €6.1 million and net profit jumping 50.09% to €2.0 million, supported by higher sales of cosmetic raw materials and increased R&D-related grants. The company posted an EBITDA of €2.2 million with a 36.34% margin and an EBIT of €2.1 million, while maintaining a net cash position of about €6.2 million.

The board approved the 2025 draft separate financial statements and proposed distributing approximately €977,000 as dividends, equal to €0.15 per share excluding treasury shares, with the rest of earnings retained. Management highlighted sustained growth driven by product innovation and cosmetic biotechnologies, ongoing R&D investment, and strengthening partnerships, positioning Arterra for further medium- to long-term expansion in cosmetic biotechnology and new geographic markets.

More about Arterra Bioscience SpA

Arterra Bioscience S.p.A. is a green biotech company focused on research and development in biotechnology, with a particular emphasis on cosmetic applications. Listed on Euronext Growth Milan since 2019, it develops high-scientific-content, sustainable and customized cosmetic biotechnologies, including bioactive ingredients and eco-friendly production processes for global markets.

Average Trading Volume: 20,025

Technical Sentiment Signal: Buy

Current Market Cap: €18.78M

See more insights into ARBS stock on TipRanks’ Stock Analysis page.